Interferon beta-1a

Summary

Interferon beta-1a is a recombinant glycoprotein cytokine produced in Chinese hamster ovary (CHO) cells, identical in amino acid sequence to natural human interferon beta. It is FDA-approved for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive MS. It reduces the frequency of clinical relapses and slows progression of disability.

Mechanism of Action

Binds to the type I interferon receptor (IFNAR1/IFNAR2) on cell surfaces, activating the JAK-STAT signaling pathway (TYK2 and JAK1), leading to upregulation of interferon-stimulated genes. This produces antiviral, antiproliferative, and immunomodulatory effects, reducing T-cell activation, decreasing blood-brain barrier disruption, and inhibiting pro-inflammatory cytokine production relevant to multiple sclerosis pathology.

Routes of Administration

Goals & Uses

• Reduction of MS relapse rateDisease ModificationHigh
• Delay of second demyelinating event (CIS)Disease PreventionHigh
• Antiviral activityInfectious DiseaseLow
• Reduction of MRI lesion burdenNeurological / AutoimmuneHigh
• Slowing disability progressionDisease ModificationHigh

Contraindications

• Severe active depression or suicidal ideationPsychiatricHigh
• Decompensated hepatic diseaseHepaticHigh
• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Thyroid disease (uncontrolled)EndocrineModerate
• Hypersensitivity to natural or recombinant interferon beta or any excipientAllergy / ImmunologyHigh

Adverse Effects

• Hepatotoxicity / elevated liver enzymesHepaticUncommon
• Hematologic abnormalities (leukopenia, thrombocytopenia, anemia)HematologicUncommon
• Neutralizing antibody formationImmunologicCommon
• Injection site reactionsLocalCommon
• Flu-like symptoms (fever, chills, myalgia, fatigue)Systemic / ConstitutionalCommon
• Depression and suicidal ideationPsychiatricUncommon

Drug Interactions

• AntidepressantsLow
• CYP450 substrates (e.g., warfarin, phenytoin)Low
• Myelosuppressive agents (e.g., azathioprine, methotrexate)Moderate
• Hepatotoxic drugs (e.g., statins, valproate, alcohol)Moderate

Population Constraints

• Elderly patients (over 65)AgeRelative
• Patients with pre-existing severe psychiatric disordersPsychiatricRelative
• Pregnant womenReproductiveRelative
• Patients with severe renal impairmentOrgan ImpairmentRelative
• Pediatric patients (under 18)AgeRelative

Regulatory Status

• European UnionApprovedApproved: Relapsing-remitting multiple sclerosis, Clinically isolated syndrome (CIS) — AvonexEMA-approved; Rebif and Avonex both hold marketing authorizations. Biosimilars also authorized in EU.
• United StatesApprovedApproved: Relapsing forms of multiple sclerosis (RRMS, CIS, active SPMS) — Avonex, Relapsing-remitting multiple sclerosis — RebifAvonex approved 1996; Rebif approved 2002. Both maintained on market with active labeling updates.
• United KingdomApprovedApproved: Relapsing-remitting multiple sclerosis, Clinically isolated syndromeAvailable on NHS under NICE guidance for patients meeting eligibility criteria (≥2 relapses in 2 years or CIS with high risk of MS).

Approved by FDA in 1996 (Avonex) and 2002 (Rebif). EMA approved. Multiple biosimilars and follow-on products exist in various jurisdictions. Rebif is approved for relapsing-remitting MS; Avonex is approved for relapsing forms of MS. Risk of serious hepatic injury and anaphylaxis noted in labeling.

Evidence & Sources

No sources recorded yet.